All posts by medical

Professor in Molecular Cell Biology job with DURHAM UNIVERSITY | 238578 – Times Higher Education (THE)

The Department of Biosciences at Durham University seeks to appoint a talented individual to the role of Professor in Molecular Cell Biology. We welcome applications from those with research and teaching interests that are consistent with research priorities in the Department and whose research is complementary to other staff in the animal cells & systems, bio-molecular interactions, or plant molecular sciences groups

The Department of Biosciences is consistently ranked in the top 5 UK Biological Sciences Departments in the Complete University Guide and was ranked 8th for Research Impact in REF2014.

We aim to appoint outstanding new academic staff to strengthen research in cross-disciplinary approaches to fundamental biological questions, potentially with impact on the bioeconomy, and to provide students with an outstanding educational and training experience. Research is focused around four key themes - animal cells & systems; biomolecular interactions; ecology, evolution & environment; and molecular plant sciences. We welcome applicants with interests in relevant areas of molecular cell biology.This post offers an exciting opportunity to make a major contribution to the development of internationally excellent research and teaching while allowing you unrivalled opportunities to progress and embed your career in an exciting and progressive institution. For more information, please visit our Department pages at https://www.dur.ac.uk/biosciences/.

We offer degree programmes in BSc Biological Sciences and a 4-year MBiol, while also contributing to Natural Sciences. Our research and teaching is supported by outstanding research infrastructure in advanced bioimaging (including super-resolution, confocal and electron microscopy), genomics, proteomics, metabolomics, high-performance computing and field research. We promote research at the interface with other disciplines.

The Department of Biosciences is particularly interested in receiving applications from women and candidates from ethnic minority backgrounds. The University is home to several networks that support researchers (e.g., women@DU, DU BAME, WHEN, and a vibrant departmental community of recent hires) https://www.dur.ac.uk/biosciences/ecrs/.

Durham University offers a generous scheme for maternity leave as well as a nursery run by the University. As an employer committed to promoting the very best talent, we also encourage applications from researchers who may have taken career breaks for family or other reasons, or who may need to consider flexible working. For more information, please visit our Department pages at http://www.dur.ac.uk/biosciences.

As one of the UK's leading universities, Durham is an incredible place to define your career while enjoying a high quality work/life balance. We are home to some of the most talented scholars and researchers from around the world who are tackling global issues and making a difference to people's lives.

The University sits in a beautiful historic city where it shares ownership of a UNESCO World Heritage Site with Durham Cathedral. A collegiate University, Durham recruits outstanding students from across the world and offers an unmatched wider student experience.

Excerpt from:
Professor in Molecular Cell Biology job with DURHAM UNIVERSITY | 238578 - Times Higher Education (THE)

Stanford Scientists Use Marlborough Company’s CODEX System in Study of Muscle Strength and Aging Published in Science – framinghamsource.com

The following is a press release from Akoya Biosciences, Inc. submitted to SOURCE through its business wire service.

***

MARLBOROUGH Akoya Biosciences, Inc., The Spatial Biology Company announced that CODEX was used for spatial phenotyping to identify the source of a protein that can reverse age-related muscle atrophy.

This study represents the first demonstration of the CODEX system in imaging muscle tissues.

The paper, titled Inhibition of prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and strength was publishedonlineinScienceon December 10from the laboratory of Helen Blau, PhD, Professor and Director of the Baxter Laboratory for Stem Cell Biology at Stanford Universitys School of Medicine.

Muscle loss due to aging, called sarcopenia, is estimated to cost the US healthcare system billions of dollars each year, and results in a reduced quality of life for patients. Dr. Blau and her team are experts in investigating mechanisms of muscle structure and function related to aging and muscle disorders.

In this study of muscle fibers in mouse models and human tissue, the authors discovered an elevated level of a protein called 15-PGDH associated with old muscles. By blocking the activity of 15-PGDH in old mice, physical strength and muscle mass were restored in the animals. The opposite happened when the researchers increased the expression of 15-PGDH in young mice, causing their muscles to atrophy and weaken, as if having an aging effect. This is the first time that the protein has been associated with aging.

A CODEX assay was used to discover and understand the source of 15-PGDH, which acts as a regulator of muscle function. CODEXs multiplexing capabilities allowed researchers to look across numerous cell types and determine where the protein was localized in the tissue and which cells were expressing it. If standard methods had been used, the study would not have had the rich data of spatial phenotyping that made a difference in the results.

We adopted CODEX for this study because the platforms multiplexing capabilities simplified our search for different cell types in a tissue sample, what proteins they express and where theyre localized, said Helen Blau, PhD, Professor of Microbiology and Immunology at Stanford University. This is how we were able to identify the cells that express 15-PGDH. Were hopeful that new ways to improve health and peoples quality of life can be uncovered with the findings from this study.

Were excited that CODEX has once again supported a novel discovery and provides researchers the ability to image protein expression and cell phenotypes within their spatial context. Studying proteinsin situbrings us as close as possible to a clinical phenotype, said Brian McKelligon, CEO of Akoya. As Akoya continues to work with an ever-increasing number of researchers across the biological spectrum, we are eager to see more of these high-impact studies that help define the future of human health.

***

Akoya Biosciences offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has two industry-leading platforms that empower investigators and researchers to gain a deeper understanding of complex diseases such as cancer, and other immune system or neurological disorders. The CODEXsystem is the only benchtop platform that can efficiently quantify more than 40 biomarkers and is ideally suited for biomarker discovery. The Phenoptics platform is the only end-to-end multiplexed immunofluorescence solution with the robustness and high throughput necessary for translational research and clinical trials. The company has its HQ in Marlborough.

Here is the original post:
Stanford Scientists Use Marlborough Company's CODEX System in Study of Muscle Strength and Aging Published in Science - framinghamsource.com

Global Artificial Photosynthesis Market Report 2020: Department of Genetics, Cell Biology, and Development, University of Minnesota, Department of…

Introduction: Global Artificial Photosynthesis Market, 2020-26

A new versatile research report on Global Artificial Photosynthesis market is aimed at promising a unique approach towards unravelling current and past market developments that collectively influence future growth predictions and market forecasts that allow market players in delivering growth specific business decisions.

The report serves as an ideal tool to instigate innovative market specific developments and subsequent growth projections. The study is a proposal and synopsis to orchestrate systematic data scavenging procedures amongst market participants.

Vendor LandscapeDepartment of Genetics, Cell Biology, and Development, University of MinnesotaDepartment of Chemistry, University of Illinois Urbana-ChampaignDepartment of Chemistry, University of CambridgeDepartment of Biochemistry and Synthetic Metabolism, Max Planck Institute for Terrestrial Department of Biochemistry and Synthetic Metabolism, Max Planck Institute for Terrestrial MicrobiologyUniversity of Bordeaux, CNRS, Centre de Recherche Paul PascalInstitut Universitaire de FranceResearch Center for Solar Energy Chemistry, and Division of Chemical Engineering, Graduate School of Engineering Science, Osaka UniversityEnergy Materials Laboratory, Korea Institute of Energy ResearchJoint Center for Artificial Photosynthesis, Lawrence Berkeley National LaboratoryTechnical Chemistry, Department of Chemistry, Chemical-Biological Centre, Ume UniversityCatalysis Division, National Chemical Laboratory

Available Sample Report in PDF Version along with Graphs and [emailprotected] https://www.orbisresearch.com/contacts/request-sample/5250231?utm_source=PoojaBis

The report also segregates various players into broad categories of novice aspirants and established market participants with elaborate success stories and investment discretion that fortify their footing amidst staggering competition and fast expanding competition isle.

Market Segments: Global Artificial Photosynthesis MarketAimed at delivering market relevant information to initiate healthy growth prognosis amongst market participants. A detailed sectional representation on market segmentation has also been flagged in the report based on which global Artificial Photosynthesis market identifies type, application and region as major segment types.

Segmentation by Type: Suspended Nanopowder PhotocatalystsPhotovoltaic Cell-driven ElectrolysersPhotoelectrochemical Cells (PECs)

Segmentation by Application: IndustrialMachinery & EquipmentAutomotiveAerospace & Defense

Report Offerings in a Gist: To identify correctly major underlying market forces that gradually underpin growth To comprehend future growth potential of the mentioned segments, inclusive of geographical outlook. A thorough evaluation of the entire competitive landscape gamut has been analyzed, isolating growth rendering strategies and industry forerunners To correctly isolate growth enablement determinants. The report lends clarity in understanding the commercial viability of the Artificial Photosynthesis market ecosystem.

Read complete report along with TOC @ https://www.orbisresearch.com/reports/index/global-artificial-photosynthesis-market-report-2020?utm_source=PoojaBis

COVID-19 Impact AnalysisThis intensively researched report presentation has been prepared in real time parlance, rendering substantial attention towards COVID-19 outbreak that has lately wreaked unprecedented damage across industries, stagnating growth.

Based on extensive geographical scope and specific vendor activities across diverse regional pockets, global Artificial Photosynthesis market is well segregated into specific nations such as Argentina and Brazil in South America. Additionally, other nations such as China, South Korea, Taiwan, Australia. Additional details on European growth hubs such as France, Italy, Germany, Netherlands have also been included in the report, followed by details on North America and MEA.

Competition EvaluationThe competitive landscape specific to global Artificial Photosynthesis market further illustrates relevant growth favoring information pertaining to the vendor landscape with a specific focus on corporate growth strategies embraced by leading players, followed religiously by other relevant contributing players along with notable investors and stakeholders striving to etch lingering growth spurts despite high intensity competition and catastrophic developments.

In-depth research findings reflected in this report opine that despite the unprecedented outbreak and lingering implications of COVID-19 and its reformatory reforms reflected across industries, the immediate and future specific implications have been thoroughly classified and elaborated in the report to encourage unbiased market discretion.

Global Artificial Photosynthesis market Key Report Highlights: This in-depth research documentation offers an illustrative overview of the entire market outlook with details on scope, executive summary and market segments The report also includes sections on competitive spectrum, highlighting major players, with detailed assessment of supply chain management, competition dynamics and growth objectives. Other crucial details on Porters Five Forces assessment, SWOT analysis and data triangulation methods have also been included in the report. Other relevant details on production patterns, growth rate, market share of each of the segments have also been pinned in the report. The report also houses crucial analytical details on revenue share and sales projections, besides volumetric estimations of each of the product segments have also been highlighted in the report to encourage unfaltering market decisions and sustainable revenue streams in global Artificial Photosynthesis market.

A dedicated chapter on COVID-19 analysis has therefore been included in this versatile report to encourage future-ready business discretion aligning with post COVID-19 market environment.

Shoot your queries at:@ https://www.orbisresearch.com/contacts/enquiry-before-buying/5250231?utm_source=PoojaBis

These crucial market relevant information are estimated to trigger tremendous growth returns and sustain market stability through the forecast tenure.

About Us:Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

Read more from the original source:
Global Artificial Photosynthesis Market Report 2020: Department of Genetics, Cell Biology, and Development, University of Minnesota, Department of...

GT Gain Therapeutics SA Announces Funding from the Swiss Innovation Agency Supporting a 3-year Research Collaboration Project with the Institute for…

- Researchers will further develop the Site-directed Enzyme Enhancement Therapy (SEE-Tx) technology for the treatment of rare genetic and neurodegenerative diseases

- The collaborative agreement unites resources from the Institute for Research in Biomedicine (IRB)-USI; Neurocentro -Ente Ospedaliero Cantonale (EOC) & GT GAIN Therapeutics, SA

LUGANO, Switzerland, Dec. 15, 2020 (GLOBE NEWSWIRE) -- GT Gain Therapeutics SA (Gain), a subsidiary of Gain Therapeutics, Inc.,a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, along with the Institute for Research in Biomedicine (IRB, affiliated to USI Universit della Svizzera Italiana) and the Neurocentro announced today that Innosuisse, the Swiss Innovation Agency, has agreed to support the CHF 1.5M project by funding approximately CHF 850,000 to leverage these world class research organizations and promote continued innovation in the area of CNS diseases. The remaining support will come from Gain to cover the cost of related headcount expenses being dedicated to the project. The award specifically supports further investigation of the mechanisms of action of Gains proprietary STAR small molecule therapeutic candidates on lysosomal dysfunction and prion-like transmission of toxic forms of protein aggregates associated with neurodegenerative diseases.

Being recognized as an Innosuisse funded innovation project reinforces the support for our innovative approach and unites us with scientists and researchers as passionate as we are to discover new therapeutic approaches using our SEE-Tx target identification platform, said Manolo Bellotto, Ph.D., President and General Manager of Gain. The specific know-how in protein quality control by Prof. Molinari at the IRB and the expertise in neurosciences of Dr. Paganetti from Neurocentro will certainly contribute to a further understanding of the mechanism of action of our molecules in rare and genetic diseases, thus accelerating their development towards the clinic.

Dr.Maurizio Molinari, group leader of the Protein Folding and Quality Control research team from the IRB added, We are honored to be collaborating with the Gain team and to evaluate Gains novel therapeutic candidates as we work to advance new, innovative treatment options for rare lysosomal disorders and neurodegenerative diseases for which there are currently few treatment options. We are grateful to the Swiss Innovation Agency for their support and look forward to initiating this critical research program.

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is redefining drug discovery with its SEE-Tx target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was originally established in 2017 with the support of its founders and institutional investors such as TiVenture, 3B Future Health Fund (formerly known as Helsinn Investment Fund) and VitaTech. It has been awarded funding support from The Michael J. Fox Foundation for Parkinsons Research (MJFF) and The Silverstein Foundation for Parkinsons with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with GT Gain Therapeutics SA., a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc. For more information, visit https://www.gaintherapeutics.com/

About the Institute for Research in Biomedicine (IRB)

The Institute for Research in Biomedicine was founded in 2000 with the clear and ambitious goal of advancing the study of human immunology, with particular emphasis on the mechanisms of host defense. The activities of the 13 research groups now extend beyond immunology to include the fields of DNA repair, rare diseases, structural and cell biology. Located in Bellinzona, capital of the Italian-speaking Canton of Ticino, the IRB is an affiliated institute of the USI Faculty of Biomedical Sciences. For more information, visit : http://www.irb.usi.ch

About Neurocentro -Ente Ospedaliero Cantonale (EOC)

The EOC multisite hospital is organized and managed as a modern company at the service of the patient. It has structures with clear segregations of functions and flexible management systems that foster innovation, accountability and simplification.Our approach favors a collegial and participatory management style. General management and hospital directors form the EOC Management Coordination Conference, physicians are directly involved in EOC management through the Clinical Coordination Conference. The other professional categories actively participate in the management of the EOC within inter-hospital groups.For more information, visit http://www.eoc.ch/en/Centri-specialistici/NSI/NSI.html

Forward-Looking Statements

Any statements in this release that are not historical facts may be considered to be forward-looking statements. Forward-looking statements are based on managements current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Such statements include, but are not limited to, statements regarding Gain Therapeutics, Inc. (Gain) expected use of the proceeds from the Series B financing round; the market opportunity for Gains product candidates; and the business strategies and development plans of Gain. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include Gains ability to: make commercially available its products and technologies in a timely manner or at all; enter into other strategic alliances, including arrangements for the development and distribution of its products; obtain intellectual property protection for its assets; accurately estimate its expenses and cash burn and raise additional funds when necessary. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Gain does not undertake any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Gain Therapeutics Investor Contact:Daniel FerryLifeSci Advisors+1 617-430-7576daniel@lifesciadvisors.com

Gain Therapeutics Media Contact:Cait Williamson, Ph.D.LifeSci Communications+1 646-751-4366cait@lifescicomms.com

Here is the original post:
GT Gain Therapeutics SA Announces Funding from the Swiss Innovation Agency Supporting a 3-year Research Collaboration Project with the Institute for...

Purdue researchers uncover blind spots at the intersection of AI and neuroscience – Purdue News Service

Findings debunk dozens of prominent published papers claiming to read minds with EEG

WEST LAFAYETTE, Ind. Is it possible to read a persons mind by analyzing the electric signals from the brain? The answer may be much more complex than most people think.

Purdue University researchers working at the intersection of artificial intelligence and neuroscience say a prominent dataset used to try to answer this question is confounded, and therefore many eye-popping findings that were based on this dataset and received high-profile recognition are false after all.

The Purdue team performed extensive tests over more than one year on the dataset, which looked at the brain activity of individuals taking part in a study where they looked at a series of images. Each individual wore a cap with dozens of electrodes while they viewed the images.

The Purdue teams work is published in IEEE Transactions on Pattern Analysis and Machine Intelligence. The team received funding from the National Science Foundation.

This measurement technique, known as electroencephalography or EEG, can provide information about brain activity that could, in principle, be used to read minds, said Jeffrey Mark Siskind, professor of electrical and computer engineering in Purdues College of Engineering. The problem is that they used EEG in a way that the dataset itself was contaminated. The study was conducted without randomizing the order of images, so the researchers were able to tell what image was being seen just by reading the timing and order information contained in EEG, instead of solving the real problem of decoding visual perception from the brain waves.

The Purdue researchers originally began questioning the dataset when they could not obtain similar outcomes from their own tests. Thats when they started analyzing the previous results and determined that a lack of randomization contaminated the dataset.

This is one of the challenges of working in cross-disciplinary research areas, said Hari Bharadwaj, an assistant professor with a joint appointment in Purdues College of Engineering and College of Health and Human Sciences. Important scientific questions often demand cross-disciplinary work. The catch is that, sometimes, researchers trained in one field are not aware of the common pitfalls that can occur when applying their ideas to another. In this case, the prior work seems to have suffered from a disconnect between AI/machine-learning scientists, and pitfalls that are well-known to neuroscientists.

The Purdue team reviewed publications that used the dataset for tasks such as object classification, transfer learning and generation of images depicting human perception and thought using brain-derived representations measured through electroencephalograms (EEGs)

The question of whether someone can read another persons mind through electric brain activity is very valid, said Ronnie Wilbur, a professor with a joint appointment in Purdues College of Health and Human Sciences and College of Liberal Arts. Our research shows that a better approach is needed.

Siskind is a well-known Purdue innovator and has worked on multiple patented technologies with the Purdue Research Foundation Office of Technology Commercialization. For more information on licensing and other opportunities with Purdue technologies, contact OTC at otcip@prf.org.

About Purdue Research Foundation Office of Technology Commercialization

The Purdue Research Foundation Office of Technology Commercialization operates one of the most comprehensive technology transfer programs among leading research universities in the U.S. Services provided by this office support the economic development initiatives of Purdue University and benefit the university's academic activities through commercializing, licensing and protecting Purdue intellectual property. The office recently moved into the Convergence Center for Innovation and Collaboration in Discovery Park District, adjacent to the Purdue campus. In fiscal year 2020, the office reported 148 deals finalized with 225 technologies signed, 408 disclosures received and 180 issued U.S. patents. The office is managed by the Purdue Research Foundation, which received the 2019 Innovation and Economic Prosperity Universities Award for Place from the Association of Public and Land-grant Universities. In 2020, IPWatchdog Institute ranked Purdue third nationally in startup creation and in the top 20 for patents. The Purdue Research Foundation is a private, nonprofit foundation created to advance the mission of Purdue University. Contact otcip@prf.org for more information.

About Purdue University

Purdue University is a top public research institution developing practical solutions to todays toughest challenges. Ranked the No. 5 Most Innovative University in the United States by U.S. News & World Report, Purdue delivers world-changing research and out-of-this-world discovery. Committed to hands-on and online, real-world learning, Purdue offers a transformative education to all. Committed to affordability and accessibility, Purdue has frozen tuition and most fees at 2012-13 levels, enabling more students than ever to graduate debt-free. See how Purdue never stops in the persistent pursuit of the next giant leap at purdue.edu.

Writer: Chris Adam, cladam@prf.orgSources: Jeffrey Siskind, qobi@purdue.edu

Hari Bharadwaj, hbharadw@purdue.edu

Ronnie Wilbur, wilbur@purdue.edu

ABSTRACT

The Perils and Pitfalls of Block Design for EEG Classification Experiments

Ren Li, Jared S. Johansen, Hamad Ahmed, Thomas V. Ilyevsky, Ronnie B. Wilbur, Hari M. Bharadwaj and Jeffrey Mark Siskind

A recent paper claims to classify brain processing evoked in subjects watching ImageNet stimuli as measured with EEG and to employ a representation derived from this processing to construct a novel object classifier. That paper, together with a series of subsequent papers, claims to achieve successful results on a wide variety of computer-vision tasks, including object classification, transfer learning, and generation of images depicting human perception and thought using brain-derived representations measured through EEG. Our novel experiments and analyses demonstrate that their results crucially depend on the block design that they employ, where all stimuli of a given class are presented together, and fail with a rapid-event design, where stimuli of different classes are randomly intermixed. The block design leads to classification of arbitrary brain states based on block-level temporal correlations that are known to exist in all EEG data, rather than stimulus-related activity. Because every trial in their test sets comes from the same block as many trials in the corresponding training sets, their block design thus leads to classifying arbitrary temporal artifacts of the data instead of stimulus-related activity. This invalidates all subsequent analyses performed on this data in multiple published papers and calls into question all of the reported results. We further show that a novel object classifier constructed with a random codebook performs as well as or better than a novel object classifier constructed with the representation extracted from EEG data, suggesting that the performance of their classifier constructed with a representation extracted from EEG data does not benefit from the brain-derived representation. Together, our results illustrate the far-reaching implications of the temporal autocorrelations that exist in all neuroimaging data for classification experiments. Further, our results calibrate the underlying difficulty of the tasks involved and caution against overly optimistic, but incorrect, claims to the contrary.

Go here to read the rest:
Purdue researchers uncover blind spots at the intersection of AI and neuroscience - Purdue News Service

Has Neuroscience Proved that the Mind Is Just the Brain? – Discovery Institute

Photo credit: Rama, CC BY-SA 2.0 FR , via Wikimedia Commons.

Last month, materialist neurologistSteven Novella(at Yale University School of Medicine) made a ratherastonishing claimin a post at hisNeurologica blog:A recent open-accessstudyof learning and decision-making in mice shows that the human mind is merely what the human brain does. Thats a lot for mice to prove.

In the study, the mice were trained to choose holes from which food is provided. Their brain activity was measured as they learned and decided which holes were best. The research looks specifically at quick and intuitive decision-making vs. decision-making that is slower and involves analysis of the situation. The investigators found that analysis-based decisions in the mice involve brain activity in the anterior cingulate cortex, which is a region of the brain in the fissure between the hemispheres.

From the standpoint of understanding the mind-brain relationship, this study is unremarkable. There is no doubt that thinking usually involves brain activity of some sort. Dualists (who think that the human mind uses the brain but is not identical with it) and materialists (who think that the mind is just what the brain does) have no disagreement here. This study details the correlative brain activity in mice, which is nice to know. But Dr. Novella takes this mundane study and draws a ludicrous conclusion:

I also feel obligated to point out that research like this completely destroys any notion of dualism that mental function exists somehow outside of or separate from the biological functioning of the brain. So far, the neuroscience hypothesis, that mental function is brain function, is working quite well. The brain is a complex biological computer, and we can figure out how it works by studying it. Even the most sophisticated cognitive processes, such as analytical decision-making, are demonstrably happening in the brain. Further, not only is there zero evidence for the dualist hypothesis, it is completely unnecessary, which is a fate in science even worse than being wrong.

Nonsense. Novella has been trying to sell his materialist ideology in the guise of neuroscience for more than a decade. This is only the most recent in a host of his bizarre claims, including his 2008assertionthat The materialist hypothesis that the brain causes consciousness has made a number of predictions, and every single prediction has been validated.

Thats a beautiful example of theDunning-Kruger effect(people overestimate their mastery of a situation they dont understand). In neuroscience, materialism is the answer only if you dont understand the questions.

Read the rest at Mind Matters, published by Discovery Institutes Bradley Center for Natural and Artificial Intelligence.

Visit link:
Has Neuroscience Proved that the Mind Is Just the Brain? - Discovery Institute

Dont Make Your Brain Dumb: The Neuroscience Of Success – Forbes

What makes a person successful?

Having a growth mindset? Being a visionary? Being born into the right family?

These may help, but a healthy brain is foundational. Without it, success is going to be far harder to come by. So what is a healthy brain, a successful brain? Its one that has high blood flow and high activity.

TheAmen Clinics perform brain imaging calledsingle photon emission computed tomography(SPECT), which assesses at blood flow and activity patterns in the brain. Since 1991, they have performed over 135,000 brain SPECT scans on patients from 120 countries. The data from SPECT teaches us the four crucial aspects of a persons brain-based success.

Daniel Amen

Here are the 4 crucial aspects of ensuring your brain stays strong, and doesnt dumb down:

1) Protect your prefrontal cortex (PFC).Youve heard me talk about this key region of the brain before. Its behind your forehead and it governs the development of your personality as well as complex behaviors. In humans, it accounts for 30% of the brains volume. Thats a lot. Cats weigh in at 3%, dogs at 7%, chimpanzees at 11% of their brains volume. The PFC is involved with executive functions, such as strategy, visioning the future, planning, focus, judgment, impulse control, and empathy. Its your internal CEO. Low PFC activity = bad decision making. Thats why protecting it is crucial. In astudyAmen published they found that 91% of traumatic brain injuries involve the PFC.

Preventing brain injuries is easy (phew!):

Daniel Amen

2) Protect your brains pleasure centers.The nucleus accumbens (NA), in both the right and left hemispheres of your brain, are involved in pleasure and motivation. Youll remember blogs Ive written about the neurotransmitter dopamine. Well the NA is lit up by the dopamine your brain releases from sex, chocolate, video games, cocaine, stimulants like coffee, high fat and high sugar foods, and fame. Most of us are familiar with the connection between dopamine and addiction, which weve been seeing with excessive video gaming for many years now. Not to bum your high, but intense pleasure actually results in substantial drops in your levels of dopamine. When repeated over time (like with heroin addiction, for instance) the NA becomes less responsive, which leads to needing more of these behaviors. Thats how addiction happens, be it to chocolate or methamphetamines.

Protect your pleasure centers by:

3) You can make your brain better.Amen Clinics is well-known for running the first and largest brain imaging and rehabilitationstudyon active and retired NFL players. Needless to say, they witnessed high levels of brain damage players, many of which had been hit in the head thousands of times. They were thrilledand surprisedto see that 80% of the players showed improvement in as little as two months on their Memory Rescue program. Since most of us have (thankfully) not been repeatedly hit in the head, there is hope for all of us to have better brainsand better lives.

The Net-Net

How does a person become successful? Thats a long answer. For starters, you can stack the deck in your favor by having a healthy brain!

More:
Dont Make Your Brain Dumb: The Neuroscience Of Success - Forbes

Decorating for the Holidays? Doctors Share Tips on How to Avoid a Trip to the ER. – Baptist Health South Florida

Here in South Florida and around the country, emergency departments see a notable increase in falls, back strains and other injuries during the holidays. According to the U.S. Consumer Product Safety Commission, injuries sustained while decorating account for some 15,000 trips a year to the ER.

Resource spoke recently with two experts from Miami Neuroscience Institute, a part of Baptist Health South Florida:

Jose Andres Restrepo, M.D., medical director for outpatient rehabilitation, specializing in physical medicine and rehabilitation, electrodiagnosis, regenerative medicine and musculoskeletal conditions including arthritis.

Raul A. Vasquez-Castellanos, M.D., neurosurgeon and director of complex spine surgery, specializing in the surgical treatment of complex spinal conditions including tumors, degenerative spine diseases, spinal deformities, scoliosis, kyphoscoliosis and neurotrauma.

We asked Drs. Restrepo and Vasquez for their thoughts on how you can prevent the most common holiday injuries and avoid the ER this holiday season.

Resource: In general, regardless of the season, what are the most common types of injuries you treat in your practice?

Dr. Vasquez: We see a lot of people who come in with nerve impingement, herniated disk, disk degeneration, chronic back pain, and simple spine fractures. Most of these result from falls or lifting heavy things. But I think it also has something to do with the fact that we live in an area with an aging population, at a time when people are living longer. As we age, our flexibility, balance and reaction times all start diminishing. We need to be mindful of our body and what its actually capable of doing.

Resource: What kind of injuries are you seeing now, as people decorate for the holidays?

Dr. Restrepo: So far this holiday season, weve seen a 10 to 15 percent increase in patients with back injuries. Most of these have been a result of decorating ones home for the holidays moving heavy furniture and boxes, falling off ladders and performing various other activities required for the job. Weve had patients complaining of everything from neck pain from looking up for long periods; back pain from bending over and lifting; hand and wrist pain from grappling with hammers, screwdrivers and other tools; ankle sprains from falling off ladders; knee sprains from awkward rotation of the knee, and bursitis of the knee from kneeling on hard surfaces for too long.

One patient came in with a back sprain and lacerations on his back. He was on a ladder stringing holiday lights along the eaves of his house, unspooling the lights he had wrapped around himself as he worked his way along the eaves. At some point he slipped and fell into the bushes below but, fortunately, his fall was broken somewhat by the lights he had wrapped around himself and the ones he had just strung around the chimney. Otherwise, his injuries might have been much worse.

Resource: Are you seeing anything different this year with holiday injuries because of the pandemic?

Dr. Vasquez: We are. What is common now, it seems especially with this second surge were seeing now is people are injuring themselves at home but reluctant to go to the ER because theyre concerned about exposure to the coronavirus. I can tell you that our facilities are perhaps the cleanest, safest spaces anywhere far more so than your local grocery store. Remember that delaying care is aggravating an existing injury. By not seeking treatment, you could possibly wind up with permanent weakness and long-term, chronic back pain. Is that a chance you want to take?

Resource: Dr. Vasquez, what recommendations do you have for avoiding injuries during the holidays?

Dr. Vasquez:

Resource: And Dr. Restrepo, what about youwhat advice can you offer that would help people avoid the ER during the holidays?

Dr. Restrepo:

Resource: If somebody is injured, should they go to Urgent Care or the ER?

Dr. Vasquez: If you suffer an acute injury from a fall, such as a broken back or broken arm, Baptist Health has Urgent Care and Urgent Care Express locations across South Florida, some of which are open 24 hours a day, seven days a week. We also have a couple of freestanding emergency departments in West Coral Way and West Kendall, and of course, there are on-campus ERs at all of our hospitals across the region. Serious back injuries requiring specialized care will be referred to our team here at Miami Neuroscience Institute. If you need us, were here 24/7 to help care for you.

Tags: ankle sprain, back pain, back sprain, Dr. Jose Andres Restrepo, Dr. Raul Vasquez-Castellanos, holiday decorating injuries, holiday decorating safety tips, Miami Neuroscience Institute

See the rest here:
Decorating for the Holidays? Doctors Share Tips on How to Avoid a Trip to the ER. - Baptist Health South Florida

Neuroscience antibodies and assays Market (2020-2026) | Where Should Participant Focus To Gain Maximum ROI | Exclusive Report By PMI – LionLowdown

The data presented in the global Neuroscience antibodies and assays market report is a compilation of data identified and collected from various sources. The scope of growth of the Neuroscience antibodies and assays market during the forecast period is identified after analyzing different data sources. The report is a valuable guidance tool that can be used to increase the market share or to develop new products that can revolutionize the market growth. The analysis of the collected data also helps in providing an overview of the Neuroscience antibodies and assays industry which further helps people make an informed choice. Latent growth factors that can manifest themselves during the forecast period are identified as they are key to the Neuroscience antibodies and assays market growth. The Neuroscience antibodies and assays report presents the data from the year 2020 to the year 2027 during the base period while forecasting the same during the forecast period for the year 2020 to the year 2027.

Get Sample Copy of This Report:

https://www.premiummarketinsights.com/sample/BRC00017587

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in This Report:

Thermo Fisher Scientific, Abcam, Bio-Rad, Merck KGAA, Cell Signaling Technology, Genscript, Rockland Immunochemicals. Bio Legend, Santa Cruz Biotechnology, Tecan, F. Hoffmann-La Roche, Siemens.

To inquire about the discount available on this Report, visit @

https://www.premiummarketinsights.com/discount/BRC00017587

Global Neuroscience antibodies and assays Market by Geography:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Europe (Turkey, Germany, Russia UK, Italy, France, etc.)

North America (the United States, Mexico, and Canada.)

South America (Brazil etc.)

The Middle East and Africa (GCC Countries and Egypt.)

This analysis provides evaluation for altering competitive dynamics:

This thorough Neuroscience antibodies and assays analysis of this shifting contest dynamics and keeps you in front of competitions;

Six-year prediction assessment primarily based mostly on the way the sector is anticipated to development;

Precisely which Neuroscience antibodies and assays application/end-user kind or Types can observe incremental increase prospects;

Which trends, barriers, and challenges could impact the development and size of Neuroscience antibodies and assays economy;

It helps to know that the vital product-type sections along with their growth;

Fundamentals of Table of Content:

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.5 Market by Application1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Neuroscience antibodies and assays Market Size2.2 Neuroscience antibodies and assays Growth Trends by Regions2.3 Industry Trends

3 Market Share by Key Players3.1 Neuroscience antibodies and assays Market Size by Manufacturers3.2 Neuroscience antibodies and assays Key Players Head office and Area Served3.3 Key Players Neuroscience antibodies and assays Product/Solution/Service3.4 Date of Enter into Neuroscience antibodies and assays Market3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product4.1 Global Neuroscience antibodies and assays Sales by Product4.2 Global Neuroscience antibodies and assays Revenue by Product4.3 Neuroscience antibodies and assays Price by Product

5 Breakdown Data by End User5.1 Overview5.2 Global Neuroscience antibodies and assays Breakdown Data by End User

Contact Us: Call: +912067274191Email: [emailprotected]

About Premiummarketinsights:

Premiummarketinsights.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Read more:
Neuroscience antibodies and assays Market (2020-2026) | Where Should Participant Focus To Gain Maximum ROI | Exclusive Report By PMI - LionLowdown

Bill Yates Appointed Vice Chancellor for Research Protections – UPJ Athletics

Bill Yates has been appointed vice chancellor for research protections, where he will lead the units in the Office of Research Protections (ORP) which aids investigators in designing and performing research studies so they meet current ethical standards and conform to all applicable laws and regulations. His appointment is effective Jan. 1, 2021.

ORP supports key research-related committees at the University, including the Institutional Review Board, Institutional Animal Care and Use Committee, Conflict of Interest Committee, Radiation Safety Committee and Institutional Biosafety Committee, and also is responsible for oversight of research integrity.

Bill brings a strong sense of practical experience in research, and a commitment to provide service to the research community, said Senior Vice Chancellor for Research Rob A. Rutenbar.

I am delighted to continue to serve the University in this new role, said Yates. He has been serving in the role on an interim basis since September 2020, when George Huber retired from the position.

Yates also is a professor in the Department of Otolaryngology in Pitts School of Medicine, and holds a secondary appointment in the Department of Neuroscience in the Kenneth P. Dietrich School of Arts and Sciences. He has been awarded continuous R01 grant funding from the National Institutes of Health since 1990 to examine vestibular system influences on autonomic regulation. In addition, he is heavily engaged in teaching of undergraduate, graduate and medical students, and was awarded the Chancellors Distinguished Teaching Award in 2010.

Yates joined Pittin 1994 from The Rockefeller University in New York City. He received a Ph.D. degree in neuroscience from the University of Florida in 1986.

Go here to see the original:
Bill Yates Appointed Vice Chancellor for Research Protections - UPJ Athletics